People | June 01, 2026
Ardena appoints Ariane de Ganck as Chief Scientific Officer
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022
This certification confirms that the facility complies with Good Manufacturing Practice requirements as referred in the EC Directive
MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease
The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,
The designation marks the first Breakthrough Therapy recognition for calderasib and is backed by positive results from the Phase 1 KANDLELIT-001 clinical trial
The study tracked patients for more than five years (median 60.7 months), with protection against disease returning emerging in under four months and continuing long term
First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors
From import dependence to global leadership, the next phase of growth must be driven not only by manufacturing scale and policy support, but also by innovation, research, and globally competitive healthcare technologies
Solvay will fund Pantys-led initiatives targeting vulnerable communities through product donations and menstrual health education programs
BPDCN typically presents with skin lesions before rapidly spreading to the bone marrow, lymph nodes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
